Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02192346 · ClinicalTrials.gov registry record · Phase 1
α-TEA in Advanced Cancer
A Phase 1 study of Metastatic Sarcoma and Metastatic Carcinoma, sponsored by Providence Health & Services.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 5
- Study locations
NCT02192346 is a Phase 1 study of Metastatic Sarcoma and Metastatic Carcinoma that has completed, run by Providence Health & Services. The registered enrollment target is 17 participants, below the 41-participant average among 12 other Metastatic Sarcoma trials with a reported enrollment target (59% lower). The trial reports 5 study locations across 1 state.
The verdict
NCT02192346, a Phase 1 study of Metastatic Sarcoma and Metastatic Carcinoma, has completed, sponsored by Providence Health & Services.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 5
- Study locations
Study Summary
The goal of this study is to find the highest dose of α-TEA that can be given to patients safely, to identify potential side effects of α-TEA, and to measure the amount of α-TEA in patients' blood. Additional goals of this study are to monitor the effect on tumors, to check for specific immune cells circulating in the blood, and to see if there are certain features of tumors that make it possible to predict the response to α-TEA.
Conditions Studied
Interventions
- DRUG 2.4 mg/kg α-TEA
- DRUG 4.8 mg/kg α-TEA
- DRUG 8.0 mg/kg α-TEA
- DRUG 9.6 mg/kg α-TEA
- DRUG 12 mg/kg α-TEA
Study Locations (5)
Oregon
- Providence Oncology & Hematology Care Clinic- Southeast - Clackamas
- Providence Oncology & Hematoloty Care Clinic- Newberg - Newberg
- Providence Oncology & Hematology Care Clinic- Willamette Falls - Oregon City
- Providence Oncology & Hematology Care Clinic- Eastside - Portland
- Providence Oncology & Hematology Care Clinic- Westside - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2014-08-04 |
| Est. Completion | 2018-05-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02192346
The ClinicalTrials.gov registry entry for NCT02192346 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 41-participant average among 12 other Metastatic Sarcoma trials with a reported enrollment target (59% lower). The listed sponsor is Providence Health & Services, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Metastatic Sarcoma appearing as the primary indexed condition, and to 5 interventions - of which 2.4 mg/kg α-TEA is the first listed.
NCT02192346 reports 5 study locations spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT02192346 about?
NCT02192346 is a clinical study titled "α-TEA in Advanced Cancer". The goal of this study is to find the highest dose of α-TEA that can be given to patients safely, to identify potential side effects of α-TEA, and to measure the amount of α-TEA in patients' blood. Additional goals of this study are to monitor the effect on tumors, to check for specific immune cell...
What is the current status of trial NCT02192346?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2014-08-04. Estimated completion is 2018-05-08.
What conditions does trial NCT02192346 study?
This clinical trial studies the following conditions: Metastatic Sarcoma, Metastatic Carcinoma, Metastatic Lymphoma.
What interventions are being tested in trial NCT02192346?
The interventions under investigation include: 2.4 mg/kg α-TEA (DRUG), 4.8 mg/kg α-TEA (DRUG), 8.0 mg/kg α-TEA (DRUG), 9.6 mg/kg α-TEA (DRUG), 12 mg/kg α-TEA (DRUG).
Who is sponsoring clinical trial NCT02192346?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02192346 being conducted?
This trial has 5 study locations across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
-
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
RECRUITING · Phase 1
-
Safety and Feasibility of Intraoperative Visualization With Cytalux in Children
RECRUITING · Phase 1
-
Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas
COMPLETED · Phase 1
-
Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
RECRUITING · NA
-
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.